The Patient-Centric Turn in Medical Liability in Singapore

2021 ◽  
pp. 245-265
Author(s):  
Calvin Wai-Loon Ho
2019 ◽  
Vol 3 (1) ◽  
pp. 97-105
Author(s):  
Mary Zuccato ◽  
Dustin Shilling ◽  
David C. Fajgenbaum

Abstract There are ∼7000 rare diseases affecting 30 000 000 individuals in the U.S.A. 95% of these rare diseases do not have a single Food and Drug Administration-approved therapy. Relatively, limited progress has been made to develop new or repurpose existing therapies for these disorders, in part because traditional funding models are not as effective when applied to rare diseases. Due to the suboptimal research infrastructure and treatment options for Castleman disease, the Castleman Disease Collaborative Network (CDCN), founded in 2012, spearheaded a novel strategy for advancing biomedical research, the ‘Collaborative Network Approach’. At its heart, the Collaborative Network Approach leverages and integrates the entire community of stakeholders — patients, physicians and researchers — to identify and prioritize high-impact research questions. It then recruits the most qualified researchers to conduct these studies. In parallel, patients are empowered to fight back by supporting research through fundraising and providing their biospecimens and clinical data. This approach democratizes research, allowing the entire community to identify the most clinically relevant and pressing questions; any idea can be translated into a study rather than limiting research to the ideas proposed by researchers in grant applications. Preliminary results from the CDCN and other organizations that have followed its Collaborative Network Approach suggest that this model is generalizable across rare diseases.


2019 ◽  
Vol 28 (3) ◽  
pp. 1356-1362
Author(s):  
Laurence Tan Lean Chin ◽  
Yu Jun Lim ◽  
Wan Ling Choo

Purpose Palliative care is a philosophy of care that encompasses holistic, patient-centric care involving patients and their family members and loved ones. Palliative care patients often have complex needs. A common challenge in managing patients near their end of life is the complexity of navigating clinical decisions and finding achievable and realistic goals of care that are in line with the values and wishes of patients. This often results in differing opinions and conflicts within the multidisciplinary team. Conclusion This article describes a tool derived from the biopsychosocial model and the 4-quadrant ethical model. The authors describe the use of this tool in managing a patient who wishes to have fried chicken despite aspiration risk and how this tool was used to encourage discussions and reduce conflict and distress within the multidisciplinary team.


2011 ◽  
Vol 10 (3) ◽  
pp. 76
Author(s):  
MARY ELLEN SCHNEIDER
Keyword(s):  

2020 ◽  
Author(s):  
M Meisenheimer ◽  
S Kattenbeck ◽  
M Frank ◽  
A Gardev ◽  
R Krampe ◽  
...  
Keyword(s):  

2019 ◽  
Vol 118 (6) ◽  
pp. 80-89
Author(s):  
T. Muthupandian ◽  
A. Sabarirajan ◽  
B. Arun ◽  
P.S. Venkateswaran ◽  
S. Manaimaran

This paper is having a major objective of finding out the service gap in hospital industry – A patient centric analysis in Coimbatore District. In the 21st century, Health conscious is very high among the people in Tamil Nadu. Before fifty years, people have limited level of hospitals and other allied health services. But today, increases of public, private, corporate and municipal hospitals providing quality services. Hence patients are expecting high quality services from the service providers. The study reveals that services provided in the hospitals have a positive and strong effect on the satisfaction of the inpatients. But reliability is the factor the hospital administrations have to consider.


2018 ◽  
Vol 69 (3) ◽  
pp. 755-757
Author(s):  
Ionut Vida Simiti

Breaking the limits of the risks for the human body, health or even the life of the patient, as assumed by the pharmaceutical producers, by using a drug off label, for its side effects, in another purpose or even against the purpose for which the drug was authorized by the National Agency of Medicine and Medical Devices, is not in itself illegal if the off label use has the common consent of both the doctor and the patient for a treatment and only for a treatment which, although a spread procedure, has little or no scientific support. But if the patient is subjected to unreasonable risks, endangering his body, health or life beyond the possible benefits of the treatment, without being informed about the lack of scientific support, the doctor is liable not only for malpractice (civil medical liability) but also for a criminal offence.


Sign in / Sign up

Export Citation Format

Share Document